Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

16. Juli 2014 aktualisiert von: Hoffmann-La Roche

Randomized Placebo-controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-modifying Anti-rheumatic Drugs (DMARDs) in Patients...

This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis. Patients receiving methotrexate treatment will be randomized to receive either a) tocilizumab 8 mg intravenous (iv) every 4 weeks + methotrexate orally (po) weekly or b) tocilizumab 8 mg iv every 4 weeks + placebo po weekly. After the first 24 weeks of blinded treatment, treatment adjustments (increase or decrease of treatment intensity) may be introduced at intervals, based on response. The anticipated time on study treatment is up to 3 years, and the target sample size is approximately 470 patients.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

556

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Brasilien
    • MG
      • Belo Horizonte, MG, Brasilien, 30130-100
    • RS
      • Porto Alegre, RS, Brasilien, 90035-903
    • SP
      • Sao Paulo, SP, Brasilien, 05403-000
      • Sao Paulo, SP, Brasilien, 04026-000
      • Sao Paulo, SP, Brasilien, 04039-004
  • Deutschland
      • Aachen, Deutschland, 52064
      • Berlin, Deutschland, 10117
      • Berlin, Deutschland, 13125
      • Dresden, Deutschland, 01307
      • Erlangen, Deutschland, 91054
      • Hamburg, Deutschland, 22081
      • Jena, Deutschland, 07747
      • Köln, Deutschland, 50924
      • Muenchen, Deutschland, 80336
      • Ratingen, Deutschland, 40882
      • Wuerzburg, Deutschland, 97080
  • Dänemark
      • Frederiksberg, Dänemark, 2000
      • Hellerup, Dänemark, 2900
      • Køge, Dänemark, 4600
  • Estland
      • Tallinn, Estland, 11312
      • Tallinn, Estland, 13419
  • Frankreich
      • Abbeville, Frankreich, 80142
      • Boulogne-billancourt, Frankreich, 92104
      • Brest, Frankreich, 29609
      • Echirolles, Frankreich, 38434
      • Le Kremlin Bicetre, Frankreich, 94275
      • Le Mans, Frankreich, 72037
      • Marseille, Frankreich, 13285
      • Marseille, Frankreich, 13385
      • Monaco, Frankreich, 98012
      • Nantes, Frankreich, 44035
      • Nice, Frankreich, 06202
      • Paris, Frankreich, 75571
      • Paris, Frankreich, 75679
      • Pierre Benite, Frankreich, 69495
      • Vandoeuvre-les-nancy, Frankreich, 54511
  • Griechenland
      • Athens, Griechenland, 11527
      • Thessaloniki, Griechenland, 54642
      • Thessaloniki, Griechenland, 54636
  • Israel
      • Afula, Israel, 18101
      • Beer Sheva, Israel, 8410101
      • Haifa, Israel, 31048
      • Haifa, Israel, 34362
      • Haifa, Israel, 34354
      • Kfar Saba, Israel, 44281
      • Ramat-Gan, Israel, 52621
      • Rishon Lezion, Israel
      • Tel Aviv, Israel, 6423906
  • Italien
      • Ancona, Italien, 60020
      • Bari, Italien, 70124
      • Perugia, Italien, 06122
      • Prato, Italien, 59100
      • Roma, Italien, 00168
  • Kroatien
      • Rijeka, Kroatien, 51000
      • Zagreb, Kroatien, 10000
  • Lettland
      • Bauska, Lettland, 3901
      • Daugavpils, Lettland, 5417
      • Liepaja, Lettland, 3400
      • Riga, Lettland, LV-1002
      • Riga, Lettland, 1038
      • Riga, Lettland, 1006
  • Niederlande
      • Amsterdam, Niederlande, 1105 AZ
      • Amsterdam, Niederlande, 1081 HV
      • Leiden, Niederlande, 2333 ZA
      • Maastricht, Niederlande, 6202 AZ
      • Nijmegen, Niederlande, 6525 GA
      • Utrecht, Niederlande, 3584 CX
  • Norwegen
      • Drammen, Norwegen, 3004
      • Gjettum, Norwegen, 1346
      • Kristiansand, Norwegen, 4604
      • Lillehammer, Norwegen, 2609
      • Moss, Norwegen, 1535
      • Oslo, Norwegen, 0319
  • Rumänien
      • Bucharest, Rumänien, 011172
      • Bucuresti, Rumänien, 020983
  • Russische Föderation
      • Barnaul, Russische Föderation, 656024
      • Ekaterinburg, Russische Föderation, 620102
      • Irkutsk, Russische Föderation, 664047
      • Izhevsk, Russische Föderation, 426009
      • Kazan, Russische Föderation, 420012
      • Khanty-Mansiysk, Russische Föderation, 628011
      • Kursk, Russische Föderation, 305007
      • Moscow, Russische Föderation, 115522
      • Novosibirsk, Russische Föderation, 630117
      • Novosibirsk, Russische Föderation, 630099
      • St Petersburg, Russische Föderation, 191015
      • Tjumen, Russische Föderation, 625023
      • UFA, Russische Föderation, 450005
      • Ulyanovsk, Russische Föderation, 432063
      • Vladivostok, Russische Föderation, 690105
  • Schweden
      • Goeteborg, Schweden, 41345
      • Umea, Schweden, 90185
  • Serbien
      • Belgrade, Serbien, 11000
      • Kragujevac, Serbien, 34000
      • Niska Banja, Serbien, 18250
      • Nova sad, Serbien, 21000
  • Spanien
      • Barcelona, Spanien, 08003
      • Madrid, Spanien, 28046
      • Madrid, Spanien, 28041
      • Madrid, Spanien, 28007
      • Madrid, Spanien, 28222
      • Sevilla, Spanien, 41009
    • Asturias
      • Oviedo, Asturias, Spanien, 33006
    • La Coruña
      • La Coruna, La Coruña, Spanien, 15006
      • Santiago De Compostela, La Coruña, Spanien, 15706
    • Madrid
      • Leganes, Madrid, Spanien, 28191
    • Vizcaya
      • Bilbao, Vizcaya, Spanien, 48013
  • Thailand
      • Bangkok, Thailand, 10300
      • Khon Kaen, Thailand, 40002
      • Pathumthani, Thailand, 12120
  • Vereinigte Staaten
    • California
      • Santa Monica, California, Vereinigte Staaten, 90404
      • Upland, California, Vereinigte Staaten, 91786
      • Whittier, California, Vereinigte Staaten, 90606
    • Florida
      • Aventura, Florida, Vereinigte Staaten, 33180
      • Naples, Florida, Vereinigte Staaten, 34102
      • Orange Park, Florida, Vereinigte Staaten, 32073
      • Plantation, Florida, Vereinigte Staaten, 33317
      • Sarasota, Florida, Vereinigte Staaten, 34239
      • South Miami, Florida, Vereinigte Staaten, 33143
      • Tamarac, Florida, Vereinigte Staaten, 33321
    • Minnesota
      • Eagan, Minnesota, Vereinigte Staaten, 55121
    • Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89128
    • Ohio
      • Mayfield, Ohio, Vereinigte Staaten, 44143
      • Middleburg Heights, Ohio, Vereinigte Staaten, 44130
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
    • Pennsylvania
      • West Reading, Pennsylvania, Vereinigte Staaten, 19611
    • South Carolina
      • Greenville, South Carolina, Vereinigte Staaten, 29601
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37205
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77004
      • San Antonio, Texas, Vereinigte Staaten, 78217
    • Washington
      • Spokane, Washington, Vereinigte Staaten, 99204
  • Vereinigtes Königreich
      • Cannock, Vereinigtes Königreich, WS11 5XY
      • Glasgow, Vereinigtes Königreich, G12 0YN
      • Leeds, Vereinigtes Königreich, LS7 4SA
      • London, Vereinigtes Königreich, SE5 9RS
      • Newcastle-upon-Tyne, Vereinigtes Königreich, NE2 4HH
      • Norwich, Vereinigtes Königreich, NR4 7UY

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • adult patients, ≥ 18 years of age;
  • moderate to severe active rheumatoid arthritis (Disease Activity Score (DAS28) > 4.4);
  • inadequate response to methotrexate;
  • on a stable dose of ≥ 15mg/week methotrexate for at least 6 weeks.

Exclusion Criteria:

  • prior treatment with a biologic;
  • Rheumatoid arthritis (RA) functional class IV;
  • known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections;
  • evidence of active malignant disease.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Tocilizumab + Methotrexate
Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
Arzneimittel: tocilizumab [RoActemra/Actemra]
tocilizumab 8 mg IV every 4 weeks.
Andere Namen:
  • RoActemra/Actemra
Arzneimittel: methotrexate
Approximately 15-17 mg methotrexate capsule orally once a week.
Placebo-Komparator: Tocilizumab + Placebo
Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.
Arzneimittel: tocilizumab [RoActemra/Actemra]
tocilizumab 8 mg IV every 4 weeks.
Andere Namen:
  • RoActemra/Actemra
Arzneimittel: placebo
Placebo matching methotrexate capsule taken orally once a week.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24
Zeitfenster: Week 24
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.
Week 24

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants With American College of Rheumatology (ACR20) Response
Zeitfenster: Baseline, Weeks 24, 52, 104
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Baseline, Weeks 24, 52, 104
Percentage of Participants With ACR50 Response
Zeitfenster: Baseline, Weeks 24, 52, 104
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Baseline, Weeks 24, 52, 104
Percentage of Participants With ACR70 Response
Zeitfenster: Baseline, Weeks 24, 52, 104
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Baseline, Weeks 24, 52, 104
Percentage of Participants With ACR90 Response
Zeitfenster: Baseline, Weeks 24, 52, 104
ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Baseline, Weeks 24, 52, 104
Time to First ACR20 Response
Zeitfenster: 104 Weeks
Time in days from first administration of study drug until ACR20 response. ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
104 Weeks
Time to First ACR50 Response
Zeitfenster: 104 Weeks
Time in days from first administration of study drug until ACR50 response. ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate).
104 Weeks
Time to First ACR70 Response
Zeitfenster: 104 Weeks
Time in days from first administration of study drug until ACR70 response. ACR70 response is defined as a ≥ 70% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
104 Weeks
Time to First ACR90 Response
Zeitfenster: 104 Weeks
Time in days from first administration of study drug until ACR90 response. ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
104 Weeks
Area Under Curve (AUC) DAS28
Zeitfenster: Baseline to Week 24
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. AUC DAS28 was averaged over study days. Analysis of Covariance was adjusted for Baseline DAS28 as a covariate and treatment group and region as fixed factors. Higher calculated AUC values are worse (indicate higher disease activity).
Baseline to Week 24
Percentage of Participants With Disease Activity Score 28 (DAS28) Remission
Zeitfenster: Week 52
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.
Week 52
Percentage of Participants With DAS28 Low Disease Activity (LDAS)
Zeitfenster: Weeks 24, 52
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2.
Weeks 24, 52
Change From Baseline in DAS28 Score
Zeitfenster: Baseline, Weeks 24, 52
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A higher value indicated higher disease activity. A negative change from Baseline indicated improvement.
Baseline, Weeks 24, 52
Percentage of Participants With Good or Moderate European League (EULAR) DAS28 Responses
Zeitfenster: Baseline, 24, 52

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.

European League Against Rheumatism (EULAR) Good response: DAS28 ≤ 3.2 or a change from Baseline < -1.2.

EULAR Moderate response: DAS28 > 3.2 to ≤ 5.1 or a change from Baseline < -0.6 to ≥ -1.2.
Baseline, 24, 52
Change From Baseline in Swollen Joint Count
Zeitfenster: Baseline, Weeks 24, 52
66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.
Baseline, Weeks 24, 52
Change From Baseline in Tender Joint Count
Zeitfenster: Baseline, Weeks 24, 52
68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.
Baseline, Weeks 24, 52
Change From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (VAS)
Zeitfenster: Baseline, Weeks 24, 52
The patients global assessment of disease activity was assessed on a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
Baseline, Weeks 24, 52
Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale (VAS)
Zeitfenster: Baseline, Weeks 24, 52
The physician global assessment of disease activity was assessed using a 0 to 100 mm horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
Baseline, Weeks 24, 52
Change From Baseline in Patient Global Assessment of Pain (VAS)
Zeitfenster: Baseline, Weeks 24, 52
The patient assessed their pain using a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change from Baseline indicated improvement.
Baseline, Weeks 24, 52
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Zeitfenster: Baseline, Weeks 24, 52
Blood was collected for Erythrocyte Sedimentation Rate (ESR) (a test that assesses tissue inflammation) and was analyzed at a local laboratory. ESR was measured in millimeters/hour (mm/hr). A reduction in the level is considered an improvement.
Baseline, Weeks 24, 52
Change From Baseline in C-Reactive Protein (CRP)
Zeitfenster: Baseline, Weeks 24, 52
Blood was collected for C-Reactive Protein (CRP) (a test for analysis of inflammatory and infectious disorders) and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL). A reduction in the level is considered an improvement.
Baseline, Weeks 24, 52
Change From Baseline in the Health Assessment Questionnaire Disability Index
Zeitfenster: Baseline, Weeks 24, 52
The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis, consisting of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. There are 4 possible responses for each question: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. The score for each of the domains is the highest (worst) score in each domain. A patient must have a domain score for at least 6 of 8 domains to calculate a valid HAQ-DI score which is the sum of domain scores, divided by the number of domains that have a score for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from Baseline indicated improvement.
Baseline, Weeks 24, 52
Change From Baseline in Total Genant Modified Sharp Scores (GSS)
Zeitfenster: Baseline, Weeks 24, 52, 104
Radiographs were taken of each hand and foot at Baseline, Weeks 24, 52 and104 and were evaluated using the Genant modified method according to Sharp. Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. Joint Narrowing Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum total erosion score in the hands is 98 and in the feet 42. The maximum scores for joint space narrowing (JSN) in the hands was104 and in the feet 48. The total score was the sum of scores for erosions and JSN. The maximum total modified GSS was 292. A lower number change from Baseline was better. Analysis of covariance model, with Baseline DAS28 as a covariate and treatment and site as fixed factors.
Baseline, Weeks 24, 52, 104
Change From Baseline in Joint Space Narrowing Score
Zeitfenster: Baseline, Weeks 24, 52, 104
A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum scores for joint space narrowing (JSN) in the hands was 104 and in the feet 48 for a total possible score of 0 to 152. A lower change from Baseline indicated a better score. Analysis of covariance model included baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.
Baseline, Weeks 24, 52, 104
Change From Baseline in Erosion Score
Zeitfenster: Baseline, Weeks 24, 52, 104
A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. The maximum erosion score in the hands was 98 and in the feet 42 for a total possible score of 0 to 140. A lower number change from Baseline indicated a better score.
Baseline, Weeks 24, 52, 104
Percentage of Participants Discontinuing Tocilizumab Due to Remission
Zeitfenster: Weeks 52, 104
The percentage of participants who stopped treatment with tocilizumab due to remission.
Weeks 52, 104
Percentage of Participants Who Withdrew Due to Lack of Sufficient Therapeutic Response
Zeitfenster: Up to 3 years
Lack of Sufficient Therapeutic Response was defined as the patient not responding to the drug as expected.
Up to 3 years
Percentage of Participants Who Withdrew Due to Safety Reasons
Zeitfenster: Up to 3 years
Safety reasons were defined as adverse events, intercurrent illness or death. An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
Up to 3 years
Change From Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL)
Zeitfenster: Baseline, Weeks 24, 52, 104
The RAQoL is a disease specific patient-reported outcome measure that determines the effect rheumatoid arthritis has on a patient's quality of life consisting of 30 questions that are answered either yes=1 or no=0 for a total possible score ranging from 0 (best) to 30 (worst). A negative change from Baseline indicated improvement.
Baseline, Weeks 24, 52, 104
Change From Baseline in Academic Medical Center (AMC) Linear Disability Scale (ALDS)
Zeitfenster: Baseline, Weeks 104
The Academic Medical Center (AMC) Linear Disability Score (ALDS) evaluates the participant's ability to perform activities of daily life consisting of 77 questions answered yes or no . The question difficulty and the patient's ability are arranged on a single hierarchical linear scale. ALDS scores range from 10 to 90 with a higher score representing higher functional status. A positive change from Baseline indicated improvement.
Baseline, Weeks 104
Area Under the Curve (AUC) From Baseline to Week 24 for ACR Response
Zeitfenster: Baseline to Week 24
ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate]. Area under the curve for ACR response to Week 24 was averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (≤ 5.5 and > 5.5) as fixed factors.
Baseline to Week 24
Area Under the Curve (AUC) From Baseline to Week 52 for ACR Response
Zeitfenster: Baseline to Week 52
ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].Area under the curve for ACR response to Week 52 averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (<=5.5 and >5.5) as fixed factors.
Baseline to Week 52
Time to Tocilizumab Remission
Zeitfenster: 104 Weeks
The time in days from initial study drug treatment to tocilizumab remission that occurred when the patient discontinued treatment with tocilizumab.
104 Weeks
Time to Drug-Free Remission
Zeitfenster: 104 Weeks
The time in days from initial study drug treatment to drug free remission that occurred when the participant was able to discontinue tocilizumab, methotrexate/placebo and open label disease-modifying antirheumatic drugs (DMARDS).
104 Weeks
Time to Flare After Tocilizumab Remission
Zeitfenster: 104 Weeks
The time in days to a flare (recurrence of disease symptoms) after the patient discontinued treatment with tocilizumab.
104 Weeks
Time to Restart of Treatment After Discontinuation/Remission
Zeitfenster: 104 Weeks
The time in days from treatment discontinuation or remission to the restart of treatment.
104 Weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Hoffmann-La Roche

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. März 2009

Primärer Abschluss (Tatsächlich)

1. August 2010

Studienabschluss (Tatsächlich)

1. Januar 2013

Studienanmeldedaten

Zuerst eingereicht

16. Dezember 2008

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

16. Dezember 2008

Zuerst gepostet (Schätzen)

17. Dezember 2008

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

18. Juli 2014

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. Juli 2014

Zuletzt verifiziert

1. Juli 2014

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • MA21488
  • 2008-001847-20

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Rheumatoide Arthritis

Klinische Studien zur tocilizumab [RoActemra/Actemra]

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Cambodia

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren